PD-1/VEGF bispecific antibody
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd.
Conditions
Non-squamous Non-small Cell Lung CancerSquamous Non-small-cell Lung Cancer
Phase 2
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
Not yet recruitingNCT07739199
Start: 2026-08-01End: 2029-12-01Target: 200Updated: 2026-08-26
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
Not yet recruitingNCT07739186
Start: 2026-08-01End: 2029-12-01Target: 120Updated: 2026-08-26